Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
New and Evolving Therapies for Hidradenitis Suppurativa (HS) - A Translational Perspective
Description
This presentation addresses hidradenitis suppurativa (HS) from a translational perspective, comparing it to more straightforward skin conditions like psoriasis and atopic dermatitis that are driven by simpler immune pathways. HS presents with a complex interplay of innate and adaptive immune responses, involving various inflammatory cells and cytokines, making treatment challenging. The disease progresses through distinct Hurley stages, highlighting the need for integrative clinical and molecular approaches to understand its pathology better. Emerging therapies are discussed, including monoclonal antibodies targeting cytokines IL-17A and IL-17F, which play a significant role in HS inflammation. Recent studies indicate the potential of targeting different pathways, such as neutrophil migration and bacterial involvement, including gram-negative infections associated with HS flare-ups. Furthermore, promising results from monoclonal antibodies and JAK inhibitors in clinical trials suggest advances in treatment efficacy, yet complications remain due to the multifactorial nature of HS. Overall, while initial treatments show success, the diverse mechanisms behind HS signify a need for ongoing research and a deeper understanding of its pathogenesis to achieve comprehensive therapeutic solutions.
View moreConclusions
- Hidradenitis suppurativa (HS) is a complex disease involving both innate and adaptive immune mechanisms, unlike psoriasis and atopic dermatitis that follow a simpler immune axis.
- The presence of unique neoplastic structures, or tunnels, distinguishes HS from other skin diseases and contributes to its inflammatory processes.
- Clinical assessments of HS need to consider both external lesions and underlying pathologies to understand the full impact of the disease.
- Current therapeutic approaches for HS involve a variety of targets without a singular immune pathway being predominant, presenting challenges for treatment.
- In early-stage HS, follicular hyperkeratosis can lead to inflammatory problems, which progress to more severe forms of the disease characterized by abscess formations and tunnels.
- Recent insights show that cytokines such as IL-17A and IL-17F play a significant role in HS pathogenesis, indicating a need for targeted therapies that address these pathways.
- Understanding HS requires a translational medicine approach that integrates clinical observations with deep molecular insights to refine treatment strategies.
- Kimball AB, et al. N Engl J Med. 2016;375:42
- Adalimumab SmPC. Available at: https://www.ema.europa.eu/en/documents/product-information/humira-epar-product-information en.pdf
- Secukinumab SmPC. Available at: https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information en.pdf
- Kimball AB, et al. Lancet. 2023;401:747-761
- Kimball AB, et al. Lancet. 2024;403:2504-2519
- Bimekizumab SmPC. Available at: https://ec.europa.eu/health/documents/community-register/2024/20240419162366/anx 162366 en.pdf
- Wolk, K., Join-Lambert, O., and Sabat, R. (2020), Aetiology and pathogenesis of hidradenitis suppurativa. Br. J. Dermatol., 183: 999-1010. https://doi.org/10.1111/bjd.19556
- Jaehwan Kim et al., comparison of HS to psoriasis, single cell transcriptomics, J Allergy Clin Immunol. 2023 Jun 2;S0091-6749(23)00705-4. doi: 10.1016/j.jaci.2023.05.012.